Stock Track | Fulgent Genetics Soars 10.59% Pre-market on Strong Q2 Results and Raised Guidance

Stock Track

Aug 01, 2025

Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.

The genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.

Adding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142777581"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142777581\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142777581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142777581","market":"us","top_or_hot":-1,"title":"Stock Track | Fulgent Genetics Soars 10.59% Pre-market on Strong Q2 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.</p>\n\n<p>Adding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Fulgent Genetics Soars 10.59% Pre-market on Strong Q2 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Fulgent Genetics Soars 10.59% Pre-market on Strong Q2 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-01 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.</p>\n\n<p>Adding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"","article_id":"1142777581","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142777581","pubTimestamp":1754046397,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"个股追踪|Fulgent Genetics盘前大涨10.59%，Q2业绩强劲，指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":1},"content_text":"Shares of Fulgent Genetics Inc. (FLGT) surged 10.59% in pre-market trading on Friday, following the company's release of better-than-expected second-quarter 2025 financial results and an upward revision of its full-year guidance.\nThe genetic testing solutions provider reported adjusted earnings per share of $0.07 for Q2, significantly beating analyst estimates of a $0.18 loss per share. Revenue for the quarter came in at $81.803 million, surpassing the consensus estimate of $76.205 million and representing a 15.17% increase from the same period last year. The company's core revenue, a key metric for its operations, reached $81.7 million for the quarter.\nAdding to the positive sentiment, Fulgent Genetics raised its 2025 core revenue guidance to $320 million, signaling strong confidence in its growth trajectory. However, the company also provided an outlook for a full-year non-GAAP loss per share of about $0.35. Despite this, investors appear to be focusing on the revenue growth and the company's ability to outperform expectations in a challenging market environment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}